Abstract：
Cardiac contractility modulation (CCM) is a novel device-based therapy used to treat patients with heart failure with reduced ejection fraction (HFrEF). In both randomized clinical trials and real-life studies, CCM has been shown to improve exercise tolerance and quality of life, reverse left ventricular remodeling, and reduce hospitalization in patients with HFrEF. In this case report, we describe for the first time the use of CCM combined with left bundle branch pacing (LBBP) cardiac resynchronization therapy pacemaker (CRT-P) implantation therapy in a female with a 22-year history of non-ischemic dilated cardiomyopathy. With the optimal medical therapy and cardiac resynchronization therapy (CRT) strategies, the patient\'s quality of life initially recovered to some extent, but began to deteriorate in the past year. Additionally, heart transplantation was not considered due to economic reasons and late stage systolic heart failure. This is the first case of CCM implantation in Fujian Province and the first report of a combined CCM and left bundle branch pacing CRT-P implantation strategy in a patient with non-ischemic etiology dilated cardiomyopathy in China.
摘要：
心脏收缩力调节（CCM）是一种基于设备的新型疗法，用于治疗射血分数降低（HFrEF）的心力衰竭患者。在随机临床试验和现实生活研究中，CCM已被证明可以提高运动耐量和生活质量，左心室重构逆转,减少HFrEF患者的住院时间。在这个案例报告中,我们首次描述了一名有22年非缺血性扩张型心肌病病史的女性患者使用CCM联合左束支起搏(LBBP)心脏再同步治疗起搏器(CRT-P)植入治疗.通过最佳的药物治疗和心脏再同步治疗（CRT）策略，患者的生活质量最初在一定程度上恢复，但在过去的一年里开始恶化。此外,由于经济原因和晚期收缩性心力衰竭,未考虑心脏移植.这是福建省首例CCM植入术，也是国内首例非缺血性病因扩张型心肌病患者CCM与左束支起搏联合CRT-P植入术方案的报道。
